CONMED (CNMD) Financials

$57.89 +2.49 (+4.50%)

Closing price 03:59 PM Eastern

Extended Trading

$57.78 -0.12 (-0.20%)

As of 06:30 PM Eastern

Annual Income Statements for CONMED

This table shows CONMED's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	132	64	-81	63	9.52	29	41	55	15	30	32
Consolidated Net Income / (Loss)	132	64	-81	63	9.52	29	41	55	15	30	32
Net Income / (Loss) Continuing Operations	132	64	-81	63	9.52	29	41	55	15	30	32
Total Pre-Tax Income	163	81	-71	73	1.60	31	51	29	19	45	47
Total Operating Income	200	121	70	110	46	79	71	47	38	51	53
Total Gross Profit	733	676	571	568	460	525	469	431	408	382	404
Total Revenue	1,307	1,245	1,045	1,011	862	955	860	796	764	719	740
Total Cost of Revenue	574	568	474	443	402	430	391	365	355	337	336
Total Operating Expenses	533	556	501	458	414	446	398	384	371	331	351
Selling, General & Admin Expense	478	503	454	415	374	400	356	352	338	303	323
Research & Development Expense	54	53	47	44	40	45	42	32	32	27	28
Total Other Income / (Expense), net	-37	-40	-141	-37	-44	-48	-21	-18	-18	-6.03	-6.11
Interest Expense	37	40	29	35	44	43	21	18	15	6.03	6.11
Other Income / (Expense), net	0.00	0.00	-112	-1.13	-0.36	-5.19	0.00	0.00	-2.94	0.00	0.00
Income Tax Expense	31	16	9.72	11	-7.91	2.61	9.80	-27	4.71	15	14
Basic Earnings per Share	$4.29	$2.10	($2.68)	$2.14	$0.33	$1.01	$1.45	$1.99	$0.53	$1.10	$1.17
Weighted Average Basic Shares Outstanding	30.91M	30.78M	30.50M	29.41M	28.94M	28.49M	28.12M	27.94M	27.80M	27.65M	27.40M
Diluted Earnings per Share	$4.25	$2.04	($2.68)	$1.94	$0.32	$0.97	$1.41	$1.97	$0.52	$1.09	$1.16
Weighted Average Diluted Shares Outstanding	30.91M	30.78M	30.50M	29.41M	28.94M	28.49M	28.12M	27.94M	27.80M	27.65M	27.40M
Weighted Average Basic & Diluted Shares Outstanding	30.91M	30.78M	30.50M	29.41M	28.94M	28.49M	28.12M	27.94M	27.80M	27.65M	27.40M
Cash Dividends to Common per Share	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80	$0.80

This table shows CONMED's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	6.04	34	49	30	20	33	16	14	1.82	27	46
Consolidated Net Income / (Loss)	6.04	34	49	30	20	33	16	14	1.82	27	46
Net Income / (Loss) Continuing Operations	6.04	34	49	30	20	33	16	14	1.82	27	46
Total Pre-Tax Income	7.67	44	56	38	25	41	20	17	2.44	-11	16
Total Operating Income	16	52	66	47	35	50	30	27	13	-1.10	24
Total Gross Profit	178	198	179	184	172	182	168	171	155	132	152
Total Revenue	321	346	317	332	312	327	305	318	295	251	275
Total Cost of Revenue	144	148	138	148	140	145	137	147	140	119	123
Total Operating Expenses	162	146	113	137	137	132	138	143	143	133	127
Selling, General & Admin Expense	149	133	100	123	123	118	125	130	130	121	115
Research & Development Expense	13	13	14	14	14	14	12	14	13	12	13
Total Other Income / (Expense), net	-8.29	-8.86	-9.25	-9.59	-9.59	-9.50	-10	-10.00	-10	-9.44	-8.54
Interest Expense	8.29	8.86	9.25	9.59	9.59	9.50	10	10.00	10	9.44	8.54
Income Tax Expense	1.64	9.89	7.47	7.54	5.71	7.61	4.44	3.69	0.63	-37	-30
Basic Earnings per Share	$0.19	$1.09	$1.59	$0.97	$0.64	$1.07	$0.52	$0.45	$0.06	$0.95	$1.51
Weighted Average Basic Shares Outstanding	30.97M	30.91M	30.86M	30.81M	30.78M	30.78M	30.74M	30.66M	30.51M	30.50M	30.47M
Diluted Earnings per Share	$0.19	$1.09	$1.57	$0.96	$0.63	$1.05	$0.50	$0.43	$0.06	$1.02	$1.48
Weighted Average Diluted Shares Outstanding	31.15M	30.91M	31.11M	31.11M	31.27M	30.78M	31.69M	31.80M	31.20M	30.50M	31.10M
Weighted Average Basic & Diluted Shares Outstanding	30.94M	30.91M	30.89M	30.83M	30.80M	30.78M	30.75M	30.74M	30.58M	30.50M	30.48M

This table details how cash moves in and out of CONMED's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	0.16	-4.65	8.10	-6.51	1.50	8.35	-15	5.19	-45	6.17	12
Net Cash From Operating Activities	167	125	33	112	65	95	75	66	40	51	65
Net Cash From Continuing Operating Activities	167	125	33	112	65	95	75	66	40	51	65
Net Income / (Loss) Continuing Operations	132	64	-81	63	9.52	29	41	55	15	30	32
Consolidated Net Income / (Loss)	132	64	-81	63	9.52	29	41	55	15	30	32
Depreciation Expense	17	16	16	16	18	19	19	20	20	19	20
Amortization Expense	61	62	58	68	68	65	43	38	35	25	26
Non-Cash Adjustments To Reconcile Net Income	38	24	134	20	13	12	14	8.47	6.49	3.42	8.41
Changes in Operating Assets and Liabilities, net	-81	-41	-94	-56	-44	-30	-42	-57	-37	-27	-21
Net Cash From Investing Activities	-13	-20	-250	-15	-14	-388	-17	-29	-266	-24	-21
Net Cash From Continuing Investing Activities	-13	-20	-250	-15	-14	-388	-17	-29	-266	-24	-21
Purchase of Property, Plant & Equipment	-13	-19	-22	-15	-13	-20	-17	-13	-15	-15	-15
Acquisitions	0.00	0.00	-228	0.00	-3.85	-368	0.00	-16	-256	-9.35	-5.27
Other Investing Activities, net	0.00	-1.00	0.00	0.00	-	-	-	-	-	-	-
Net Cash From Financing Activities	-151	-110	225	-102	-52	301	-72	-35	183	-13	-26
Net Cash From Continuing Financing Activities	-151	-110	225	-102	-52	301	-72	-35	183	-13	-26
Repayment of Debt	-820	-764	-911	-451	-228	-651	-181	-168	-179	-121	-85
Repurchase of Common Equity	0.00	0.00	-70	0.00	0.00	-	-	-	-	-	-17
Payment of Dividends	-25	-25	-24	-23	-23	-23	-22	-22	-22	-22	-22
Issuance of Debt	751	692	1,260	379	202	1,002	153	155	400	143	113
Issuance of Common Equity	0.00	0.00	72	0.00	0.00	31	0.00	0.00	-	-	-
Other Financing Activities, net	-57	-14	-102	-6.22	-2.67	-58	-21	0.00	-17	-13	-16
Effect of Exchange Rate Changes	-2.72	0.47	-0.74	-1.87	2.67	-0.01	-1.04	3.56	-1.48	-7.76	-6.22
Cash Interest Paid	33	34	26	22	30	27	20	16	14	5.43	5.53
Cash Income Taxes Paid	15	20	9.07	8.56	9.12	11	11	8.87	9.59	10	10

This table details how cash moves in and out of CONMED's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	11	-14	9.60	-4.99	9.56	-6.21	2.65	1.35	-2.45	-4.41	-20
Net Cash From Operating Activities	42	43	51	43	29	56	46	27	-3.85	-12	26
Net Cash From Continuing Operating Activities	42	43	51	43	29	56	46	27	-3.85	-12	26
Net Income / (Loss) Continuing Operations	6.04	34	49	30	20	33	16	14	1.82	27	46
Consolidated Net Income / (Loss)	6.04	34	49	30	20	33	16	14	1.82	27	46
Depreciation Expense	4.24	4.20	4.20	4.17	4.05	4.05	3.93	4.17	4.06	4.03	3.94
Amortization Expense	15	15	15	15	15	15	15	15	15	15	15
Non-Cash Adjustments To Reconcile Net Income	14	18	6.12	6.97	6.24	5.92	6.19	6.42	5.73	5.76	5.75
Changes in Operating Assets and Liabilities, net	1.94	-28	-23	-13	-16	-2.10	4.69	-13	-31	-63	-45
Net Cash From Investing Activities	-2.93	-4.04	-3.42	-3.59	-2.04	-4.86	-5.39	-5.53	-4.25	-6.32	-91
Net Cash From Continuing Investing Activities	-2.93	-4.04	-3.42	-3.59	-2.04	-4.86	-5.39	-5.53	-4.25	-6.32	-91
Purchase of Property, Plant & Equipment	-3.78	-4.04	-3.42	-3.59	-2.04	-4.86	-5.39	-4.53	-4.25	-5.68	-6.71
Other Investing Activities, net	0.85	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-28	-51	-39	-44	-17	-59	-37	-20	5.35	12	47
Net Cash From Continuing Financing Activities	-28	-51	-39	-44	-17	-59	-37	-20	5.35	12	47
Repayment of Debt	-181	-186	-166	-230	-238	-219	-198	-185	-162	-125	-92
Payment of Dividends	-6.18	-6.18	-6.16	-6.16	-6.15	-6.15	-6.15	-6.11	-6.10	-6.10	-6.09
Issuance of Debt	166	150	142	205	254	180	167	172	173	143	145
Other Financing Activities, net	-7.17	-8.80	-8.66	-13	-27	-14	-	-	0.00	-0.80	-
Effect of Exchange Rate Changes	0.82	-2.24	0.65	-0.62	-0.51	1.02	-0.85	-0.00	0.30	1.99	-1.31

This table presents CONMED's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	2,306	2,300	2,298	1,766	1,752	1,775	1,369	1,358	1,329	1,102	1,098
Total Current Assets	640	616	581	460	417	397	374	357	331	360	381
Cash & Equivalents	24	24	29	21	27	26	18	33	27	73	66
Accounts Receivable	238	242	191	184	177	189	182	167	148	134	129
Inventories, net	347	318	332	232	195	165	155	141	136	133	148
Prepaid Expenses	31	31	29	24	17	18	21	16	19	20	22
Plant, Property, & Equipment, net	116	121	116	109	111	119	113	116	122	125	133
Total Noncurrent Assets	1,550	1,564	1,601	1,197	1,224	1,259	882	885	876	616	584
Goodwill	805	807	815	618	618	618	400	402	398	261	256
Intangible Assets	618	649	682	471	502	533	413	415	420	308	316
Noncurrent Deferred & Refundable Income Taxes	11	11	9.65	9.66	6.84	5.66	5.16	4.72	3.71	4.24	1.40
Other Noncurrent Operating Assets	116	96	94	99	97	102	63	63	56	43	9.55
Total Liabilities & Shareholders' Equity	2,306	2,300	2,298	1,766	1,752	1,775	1,369	1,358	1,329	1,102	1,098
Total Liabilities	1,344	1,466	1,552	981	1,043	1,065	707	727	748	517	517
Total Current Liabilities	278	311	297	197	190	188	161	150	114	120	116
Short-Term Debt	0.72	0.71	70	12	18	14	18	15	10	1.34	1.23
Accounts Payable	102	88	73	58	53	56	53	42	42	35	24
Current Employee Benefit Liabilities	65	70	55	60	50	54	43	34	32	32	36
Other Current Liabilities	110	152	99	66	68	65	46	59	30	52	52
Total Noncurrent Liabilities	1,065	1,155	1,255	784	852	877	546	577	634	397	401
Long-Term Debt	905	973	985	672	735	755	439	472	488	269	240
Noncurrent Deferred & Payable Income Tax Liabilities	74	61	67	69	58	74	81	78	119	103	112
Other Noncurrent Operating Liabilities	86	121	204	43	59	47	26	27	27	24	49
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	963	834	746	785	709	710	662	631	581	585	581
Total Preferred & Common Equity	963	834	746	785	709	710	662	631	581	585	581
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	963	834	746	785	709	710	662	631	581	585	581
Common Stock	477	447	414	397	383	380	342	334	330	325	320
Retained Earnings	560	453	413	497	457	471	465	440	407	415	406
Treasury Stock	-16	-15	-23	-54	-68	-81	-89	-94	-97	-101	-105
Accumulated Other Comprehensive Income / (Loss)	-59	-50	-58	-54	-64	-59	-56	-49	-59	-54	-40

This table presents CONMED's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	2,298	2,316	2,286	2,309	2,326	2,323	2,320	2,292
Total Current Assets	639	641	624	636	626	616	610	574
Cash & Equivalents	35	38	29	34	31	28	26	33
Accounts Receivable	221	231	239	241	230	229	213	197
Inventories, net	355	343	322	322	326	327	335	305
Prepaid Expenses	28	29	33	38	39	31	35	39
Plant, Property, & Equipment, net	116	117	117	118	120	117	115	114
Total Noncurrent Assets	1,543	1,557	1,545	1,556	1,580	1,590	1,595	1,604
Goodwill	806	807	806	806	815	816	815	814
Intangible Assets	610	626	633	641	657	666	674	689
Other Noncurrent Operating Assets	127	125	105	108	107	109	106	100
Total Liabilities & Shareholders' Equity	2,298	2,316	2,286	2,309	2,326	2,323	2,320	2,292
Total Liabilities	1,320	1,383	1,404	1,455	1,529	1,543	1,568	1,576
Total Current Liabilities	283	282	266	291	376	353	321	209
Short-Term Debt	0.71	0.72	0.72	0.69	71	70	70	0.24
Accounts Payable	96	105	101	102	82	79	77	74
Current Employee Benefit Liabilities	58	61	55	50	60	55	49	54
Other Current Liabilities	129	116	109	139	163	150	125	80
Total Noncurrent Liabilities	1,037	1,101	1,137	1,163	1,153	1,189	1,247	1,367
Long-Term Debt	891	940	965	990	942	971	995	1,036
Noncurrent Deferred & Payable Income Tax Liabilities	70	66	65	64	67	66	66	113
Other Noncurrent Operating Liabilities	76	95	107	109	144	152	186	218
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	978	933	882	855	796	780	752	716
Total Preferred & Common Equity	978	933	882	855	796	780	752	716
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	978	933	882	855	796	780	752	716
Common Stock	489	471	465	458	440	433	420	407
Retained Earnings	560	533	490	466	426	416	408	392
Treasury Stock	-15	-16	-19	-20	-15	-16	-21	-23
Accumulated Other Comprehensive Income / (Loss)	-57	-55	-54	-50	-54	-53	-55	-60

This table displays calculated financial ratios and metrics derived from CONMED's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.00%	19.06%	3.45%	17.18%	-9.70%	11.11%	7.94%	4.31%	6.17%	-2.82%	-2.97%
EBITDA Growth	39.97%	511.40%	-83.20%	46.76%	-16.65%	18.70%	26.19%	17.15%	-5.27%	-3.52%	-5.61%
EBIT Growth	66.10%	387.44%	-138.64%	137.85%	-38.24%	3.68%	51.92%	35.13%	-32.13%	-3.05%	-6.59%
NOPAT Growth	69.18%	96.13%	-47.76%	-65.64%	276.70%	26.09%	-36.55%	217.87%	-17.52%	-5.04%	-9.23%
Net Income Growth	105.44%	179.99%	-228.84%	557.16%	-66.75%	-29.95%	-26.37%	278.39%	-51.92%	-5.26%	-10.43%
EPS Growth	108.33%	176.12%	-238.14%	506.25%	-67.01%	-31.21%	-28.43%	278.85%	-52.29%	-6.03%	-9.38%
Operating Cash Flow Growth	33.20%	275.69%	-70.15%	73.20%	-32.17%	27.35%	13.93%	64.40%	-21.67%	-21.88%	-19.49%
Free Cash Flow Firm Growth	22.26%	130.69%	-441.69%	-72.55%	204.30%	-779.35%	-27.92%	123.79%	-3,256.86%	-84.00%	166.78%
Invested Capital Growth	3.38%	0.70%	22.23%	0.97%	-1.25%	31.93%	1.51%	3.20%	34.24%	3.57%	-1.44%
Revenue Q/Q Growth	1.47%	6.52%	-2.16%	2.14%	-1.38%	2.40%	2.37%	2.37%	1.74%	-0.55%	-1.13%
EBITDA Q/Q Growth	0.82%	35.06%	-82.39%	5.88%	-2.86%	5.75%	2.11%	12.78%	2.47%	-4.29%	0.30%
EBIT Q/Q Growth	1.17%	73.98%	-138.72%	11.72%	-6.06%	2.40%	3.86%	29.07%	-1.03%	-7.45%	1.75%
NOPAT Q/Q Growth	-0.15%	-29.14%	-35.35%	-11.63%	9,444.36%	9.95%	-43.31%	207.66%	4.66%	-9.30%	3.47%
Net Income Q/Q Growth	0.52%	11.19%	2.59%	0.49%	2,960.13%	-2.45%	-43.18%	258.00%	-7.24%	-10.26%	3.58%
EPS Q/Q Growth	0.95%	1.49%	9.15%	-4.90%	1,700.00%	-3.00%	-44.05%	251.79%	-5.45%	-11.38%	3.57%
Operating Cash Flow Q/Q Growth	-7.25%	118.55%	-57.63%	13.90%	-24.31%	20.48%	5.50%	12.18%	3.90%	-20.90%	-2.49%
Free Cash Flow Firm Q/Q Growth	-3.51%	9.01%	-33.87%	-12.41%	575.97%	11.40%	-42.52%	72.56%	6.49%	-81.16%	78.57%
Invested Capital Q/Q Growth	0.48%	0.30%	3.01%	0.66%	0.74%	-0.79%	1.64%	2.97%	-0.56%	1.22%	-2.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.08%	54.33%	54.64%	56.21%	53.37%	54.94%	54.57%	54.12%	53.48%	53.08%	54.60%
EBITDA Margin	21.26%	15.95%	3.11%	19.12%	15.27%	16.54%	15.48%	13.25%	11.79%	13.22%	13.31%
Operating Margin	15.33%	9.69%	6.70%	10.86%	5.33%	8.28%	8.29%	5.89%	4.93%	7.12%	7.13%
EBIT Margin	15.33%	9.69%	-4.01%	10.74%	5.29%	7.74%	8.29%	5.89%	4.55%	7.12%	7.13%
Profit (Net Income) Margin	10.13%	5.18%	-7.71%	6.19%	1.10%	3.00%	4.75%	6.97%	1.92%	4.24%	4.35%
Tax Burden Percent	81.23%	79.75%	113.72%	85.55%	593.70%	91.66%	80.65%	193.12%	75.69%	67.56%	68.97%
Interest Burden Percent	81.38%	67.02%	168.89%	67.32%	3.51%	42.24%	71.04%	61.22%	55.78%	88.21%	88.42%
Effective Tax Rate	18.77%	20.25%	0.00%	14.45%	-493.70%	8.34%	19.35%	-93.12%	24.31%	32.44%	31.03%
Return on Invested Capital (ROIC)	8.97%	5.41%	3.05%	6.51%	18.91%	5.68%	5.26%	8.48%	3.11%	4.49%	4.78%
ROIC Less NNEP Spread (ROIC-NNEP)	5.66%	2.20%	-12.30%	2.00%	-16.98%	-1.75%	1.53%	0.88%	-1.03%	2.31%	2.27%
Return on Net Nonoperating Assets (RNNOA)	5.77%	2.75%	-13.57%	1.86%	-17.57%	-1.51%	1.06%	0.67%	-0.59%	0.74%	0.64%
Return on Equity (ROE)	14.74%	8.16%	-10.53%	8.37%	1.34%	4.17%	6.32%	9.16%	2.52%	5.23%	5.42%
Cash Return on Invested Capital (CROIC)	5.65%	4.72%	-16.96%	5.54%	20.17%	-21.86%	3.76%	5.34%	-26.13%	0.99%	6.23%
Operating Return on Assets (OROA)	8.70%	5.25%	-2.07%	6.17%	2.59%	4.70%	5.23%	3.49%	2.86%	4.65%	4.82%
Return on Assets (ROA)	5.75%	2.80%	-3.97%	3.56%	0.54%	1.82%	3.00%	4.13%	1.21%	2.77%	2.94%
Return on Common Equity (ROCE)	14.74%	8.16%	-10.53%	8.37%	1.34%	4.17%	6.32%	9.16%	2.52%	5.23%	5.42%
Return on Equity Simple (ROE_SIMPLE)	13.76%	7.73%	-10.81%	7.96%	1.34%	4.03%	6.17%	8.79%	2.53%	5.21%	5.54%
Net Operating Profit after Tax (NOPAT)	163	96	49	94	273	73	58	91	29	35	36
NOPAT Margin	12.45%	7.73%	4.69%	9.29%	31.67%	7.59%	6.69%	11.38%	3.73%	4.81%	4.92%
Net Nonoperating Expense Percent (NNEP)	3.31%	3.21%	15.34%	4.51%	35.89%	7.42%	3.73%	7.60%	4.14%	2.18%	2.51%
Return On Investment Capital (ROIC_SIMPLE)	8.71%	5.32%	2.72%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	43.92%	45.67%	45.36%	43.79%	46.63%	45.06%	45.43%	45.88%	46.52%	46.92%	45.40%
SG&A Expenses to Revenue	36.59%	40.41%	43.43%	41.04%	43.34%	41.90%	41.37%	44.17%	44.32%	42.14%	43.71%
R&D to Revenue	4.16%	4.23%	4.51%	4.31%	4.69%	4.76%	4.91%	4.06%	4.22%	3.82%	3.75%
Operating Expenses to Revenue	40.76%	44.64%	47.94%	45.35%	48.04%	46.66%	46.28%	48.23%	48.55%	45.96%	47.47%
Earnings before Interest and Taxes (EBIT)	200	121	-42	109	46	74	71	47	35	51	53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	278	199	32	193	132	158	133	105	90	95	99
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.20	3.99	3.56	5.17	4.40	4.31	2.61	2.13	1.97	1.90	1.91
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	68.49	128.74
Price to Revenue (P/Rev)	1.62	2.68	2.54	4.02	3.62	3.20	2.01	1.69	1.50	1.55	1.50
Price to Earnings (P/E)	15.97	51.69	0.00	64.97	327.84	106.92	42.25	24.25	77.90	36.50	34.50
Dividend Yield	1.17%	0.74%	0.92%	0.58%	0.73%	0.74%	1.30%	1.66%	1.95%	1.99%	1.98%
Earnings Yield	6.26%	1.93%	0.00%	1.54%	0.31%	0.94%	2.37%	4.12%	1.28%	2.74%	2.90%
Enterprise Value to Invested Capital (EV/IC)	1.62	2.40	2.08	3.26	2.68	2.62	1.97	1.66	1.53	1.67	1.70
Enterprise Value to Revenue (EV/Rev)	2.29	3.44	3.52	4.68	4.46	3.98	2.52	2.26	2.11	1.82	1.74
Enterprise Value to EBITDA (EV/EBITDA)	10.78	21.57	113.32	24.46	29.21	24.07	16.27	17.06	17.92	13.80	13.05
Enterprise Value to EBIT (EV/EBIT)	14.95	35.50	0.00	43.53	84.25	51.44	30.37	38.34	46.45	25.63	24.36
Enterprise Value to NOPAT (EV/NOPAT)	18.41	44.52	75.04	50.36	14.08	52.45	37.66	19.85	56.58	37.93	35.31
Enterprise Value to Operating Cash Flow (EV/OCF)	17.94	34.16	110.29	42.29	59.60	39.98	28.99	27.44	40.45	25.76	19.73
Enterprise Value to Free Cash Flow (EV/FCFF)	29.23	51.08	0.00	59.13	13.21	0.00	52.68	31.56	0.00	172.68	27.09
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.94	1.17	1.41	0.87	1.06	1.08	0.69	0.77	0.86	0.46	0.42
Long-Term Debt to Equity	0.94	1.17	1.32	0.86	1.04	1.06	0.66	0.75	0.84	0.46	0.41
Financial Leverage	1.02	1.25	1.10	0.93	1.04	0.86	0.69	0.76	0.57	0.32	0.28
Leverage Ratio	2.56	2.91	2.65	2.35	2.48	2.29	2.11	2.22	2.09	1.89	1.84
Compound Leverage Factor	2.09	1.95	4.48	1.58	0.09	0.97	1.50	1.36	1.16	1.66	1.63
Debt to Total Capital	48.48%	53.86%	58.59%	46.57%	51.52%	51.97%	40.82%	43.52%	46.20%	31.64%	29.35%
Short-Term Debt to Total Capital	0.04%	0.04%	3.87%	0.83%	1.26%	0.92%	1.64%	1.31%	0.95%	0.16%	0.15%
Long-Term Debt to Total Capital	48.44%	53.82%	54.72%	45.74%	50.27%	51.05%	39.19%	42.20%	45.25%	31.48%	29.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	51.52%	46.14%	41.41%	53.43%	48.48%	48.03%	59.18%	56.49%	53.80%	68.36%	70.65%
Debt to EBITDA	3.26	4.91	32.48	3.54	5.72	4.87	3.43	4.61	5.54	2.85	2.45
Net Debt to EBITDA	3.17	4.78	31.59	3.43	5.51	4.70	3.30	4.30	5.23	2.09	1.78
Long-Term Debt to EBITDA	3.26	4.90	30.34	3.48	5.58	4.78	3.29	4.47	5.42	2.83	2.44
Debt to NOPAT	5.57	10.13	21.51	7.29	2.76	10.60	7.94	5.37	17.48	7.83	6.63
Net Debt to NOPAT	5.42	9.87	20.92	7.07	2.66	10.25	7.64	5.01	16.52	5.74	4.81
Long-Term Debt to NOPAT	5.56	10.12	20.09	7.16	2.69	10.41	7.63	5.20	17.12	7.79	6.60
Altman Z-Score	2.33	2.51	1.82	3.83	2.89	2.91	2.93	2.45	2.20	2.89	2.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.30	1.98	1.96	2.34	2.19	2.11	2.33	2.38	2.90	3.01	3.29
Quick Ratio	0.94	0.86	0.74	1.04	1.08	1.14	1.24	1.33	1.54	1.72	1.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	102	84	-273	80	291	-279	41	57	-240	7.59	47
Operating Cash Flow to CapEx	1,276.12%	658.62%	153.16%	751.85%	659.42%	474.10%	452.54%	510.56%	416.51%	339.24%	422.92%
Free Cash Flow to Firm to Interest Expense	2.75	2.11	-9.45	2.25	6.61	-6.54	1.99	3.13	-15.61	1.26	7.77
Operating Cash Flow to Interest Expense	4.48	3.15	1.15	3.15	1.46	2.23	3.62	3.60	2.60	8.44	10.67
Operating Cash Flow Less CapEx to Interest Expense	4.13	2.67	0.40	2.73	1.24	1.76	2.82	2.90	1.97	5.95	8.14
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.54	0.51	0.57	0.49	0.61	0.63	0.59	0.63	0.65	0.68
Accounts Receivable Turnover	5.45	5.74	5.57	5.60	4.71	5.15	4.93	5.05	5.41	5.47	5.49
Inventory Turnover	1.73	1.75	1.68	2.08	2.24	2.70	2.64	2.64	2.64	2.40	2.31
Fixed Asset Turnover	11.05	10.53	9.31	9.18	7.49	8.23	7.49	6.69	6.17	5.56	5.43
Accounts Payable Turnover	6.03	7.04	7.21	7.94	7.36	7.86	8.17	8.73	9.30	11.54	13.12
Days Sales Outstanding (DSO)	67.02	63.58	65.50	65.20	77.50	70.82	74.00	72.25	67.43	66.78	66.51
Days Inventory Outstanding (DIO)	211.45	208.87	217.03	175.87	163.13	135.36	138.34	138.52	138.33	152.24	158.25
Days Payable Outstanding (DPO)	60.56	51.88	50.64	45.98	49.59	46.42	44.65	41.81	39.24	31.62	27.81
Cash Conversion Cycle (CCC)	217.92	220.56	231.89	195.08	191.04	159.77	167.70	168.96	166.53	187.40	196.96
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,844	1,784	1,771	1,449	1,435	1,453	1,102	1,085	1,052	783	756
Invested Capital Turnover	0.72	0.70	0.65	0.70	0.60	0.75	0.79	0.75	0.83	0.93	0.97
Increase / (Decrease) in Invested Capital	60	12	322	14	-18	352	16	34	268	27	-11
Enterprise Value (EV)	2,995	4,282	3,680	4,727	3,846	3,803	2,166	1,799	1,613	1,311	1,286
Market Capitalization	2,114	3,332	2,654	4,063	3,120	3,060	1,726	1,346	1,142	1,113	1,111
Book Value per Share	$31.16	$27.13	$24.46	$26.86	$24.79	$25.03	$23.54	$22.60	$20.87	$21.12	$21.12
Tangible Book Value per Share	($14.90)	($20.23)	($24.66)	($10.36)	($14.37)	($15.52)	($5.38)	($6.64)	($8.50)	$0.59	$0.31
Total Capital	1,868	1,808	1,800	1,470	1,463	1,479	1,119	1,118	1,079	856	823
Total Debt	906	974	1,055	685	754	769	457	486	498	271	241
Total Long-Term Debt	905	973	985	672	735	755	439	472	488	269	240
Net Debt	881	950	1,026	664	726	743	439	454	471	198	175
Capital Expenditures (CapEx)	13	19	22	15	9.79	20	17	13	9.58	15	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	338	281	325	255	218	197	214	189	199	169	200
Debt-free Net Working Capital (DFNWC)	363	306	354	276	245	223	232	221	227	241	266
Net Working Capital (NWC)	362	305	285	263	226	209	213	207	217	240	265
Net Nonoperating Expense (NNE)	30	32	130	31	264	44	17	35	14	4.07	4.21
Net Nonoperating Obligations (NNO)	881	950	1,026	664	726	743	439	454	471	198	175
Total Depreciation and Amortization (D&A)	78	78	74	85	86	84	62	59	55	44	46
Debt-free, Cash-free Net Working Capital to Revenue	25.87%	22.60%	31.13%	25.22%	25.22%	20.63%	24.92%	23.71%	26.11%	23.49%	27.04%
Debt-free Net Working Capital to Revenue	27.74%	24.55%	33.90%	27.28%	28.39%	23.34%	26.96%	27.81%	29.70%	33.57%	36.00%
Net Working Capital to Revenue	27.69%	24.50%	27.23%	26.07%	26.26%	21.91%	24.83%	25.96%	28.36%	33.38%	35.83%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$4.29	$2.10	($2.68)	$2.14	$0.33	$1.01	$1.45	$1.99	$0.53	$1.10	$1.17
Adjusted Weighted Average Basic Shares Outstanding	30.91M	30.78M	30.50M	29.41M	28.94M	28.49M	28.15M	27.98M	27.84M	27.71M	27.57M
Adjusted Diluted Earnings per Share	$4.25	$2.04	($2.68)	$1.94	$0.32	$0.97	$1.41	$1.97	$0.52	$1.09	$1.16
Adjusted Weighted Average Diluted Shares Outstanding	30.91M	30.78M	30.50M	29.41M	28.94M	28.49M	28.15M	27.98M	27.84M	27.71M	27.57M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.91M	30.78M	30.50M	29.41M	28.94M	28.49M	28.15M	27.98M	27.84M	27.71M	27.57M
Normalized Net Operating Profit after Tax (NOPAT)	163	96	49	94	32	73	58	33	29	35	36
Normalized NOPAT Margin	12.45%	7.73%	4.69%	9.29%	3.73%	7.59%	6.69%	4.13%	3.73%	4.81%	4.92%
Pre Tax Income Margin	12.47%	6.49%	-6.78%	7.23%	0.19%	3.27%	5.89%	3.61%	2.54%	6.28%	6.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.37	3.03	-1.45	3.06	1.04	1.73	3.45	2.58	2.26	8.49	8.64
NOPAT to Interest Expense	4.36	2.42	1.70	2.65	6.20	1.70	2.78	4.98	1.86	5.73	5.96
EBIT Less CapEx to Interest Expense	5.02	2.55	-2.21	2.64	0.81	1.26	2.65	1.87	1.64	6.00	6.12
NOPAT Less CapEx to Interest Expense	4.01	1.94	0.94	2.23	5.98	1.23	1.99	4.27	1.23	3.24	3.44
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	18.62%	38.01%	-29.73%	37.18%	239.76%	78.97%	54.93%	40.20%	151.48%	72.48%	68.21%
Augmented Payout Ratio	18.62%	38.01%	-116.02%	37.18%	239.76%	78.97%	54.93%	40.20%	151.48%	72.48%	120.59%

This table displays calculated financial ratios and metrics derived from CONMED's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.88%	5.78%	3.98%	4.55%	5.69%	30.37%	10.72%	14.60%	21.93%	-8.43%	10.55%
EBITDA Growth	-34.53%	3.24%	71.21%	41.21%	69.45%	284.02%	14.66%	167.91%	-19.96%	-68.76%	-6.15%
EBIT Growth	-54.42%	4.61%	116.85%	71.81%	175.71%	4,679.01%	24.96%	131.32%	-43.42%	-102.94%	-5.22%
NOPAT Growth	-53.75%	-0.47%	140.96%	74.17%	187.23%	5,417.64%	-66.78%	26.23%	-50.94%	-102.50%	211.07%
Net Income Growth	-69.37%	2.07%	209.30%	118.29%	983.51%	24.40%	-65.68%	108.16%	-87.85%	8.75%	208.74%
EPS Growth	-69.84%	3.81%	214.00%	123.26%	950.00%	2.94%	-66.22%	107.61%	-87.23%	36.00%	214.89%
Operating Cash Flow Growth	42.63%	-23.15%	11.00%	62.36%	856.98%	586.25%	78.14%	42.32%	-1,272.87%	-134.33%	21.21%
Free Cash Flow Firm Growth	-256.88%	-168.98%	100.76%	107.23%	102.15%	108.81%	83.14%	-7.44%	-1,015.19%	-2,027.08%	-2,729.31%
Invested Capital Growth	1.25%	3.38%	3.19%	1.42%	1.15%	0.70%	3.42%	11.91%	20.97%	22.23%	19.44%
Revenue Q/Q Growth	-7.14%	9.23%	-4.64%	6.35%	-4.52%	7.38%	-4.12%	7.51%	17.78%	-8.80%	-0.76%
EBITDA Q/Q Growth	-50.45%	-15.48%	28.29%	21.84%	-21.85%	40.16%	5.81%	46.21%	77.10%	-58.15%	162.67%
EBIT Q/Q Growth	-69.60%	-20.10%	39.48%	34.54%	-30.23%	65.63%	10.51%	115.91%	1,258.67%	-104.52%	127.70%
NOPAT Q/Q Growth	-69.08%	-28.78%	51.46%	38.65%	-33.46%	72.43%	9.48%	128.66%	1,331.95%	-101.08%	316.00%
Net Income Q/Q Growth	-82.12%	-31.09%	63.41%	52.09%	-40.40%	108.82%	15.33%	654.92%	-93.16%	-42.40%	127.42%
EPS Q/Q Growth	-82.57%	-30.57%	63.54%	52.38%	-40.00%	110.00%	16.28%	616.67%	-94.12%	-31.08%	126.19%
Operating Cash Flow Q/Q Growth	-4.16%	-15.36%	18.24%	48.71%	-48.36%	22.26%	72.94%	793.35%	66.83%	-144.79%	38.15%
Free Cash Flow Firm Q/Q Growth	48.32%	-7,487.59%	-97.83%	89.35%	-77.27%	180.87%	79.23%	43.75%	6.79%	-54.76%	-32.40%
Invested Capital Q/Q Growth	-0.53%	0.48%	0.90%	0.40%	1.56%	0.30%	-0.83%	0.14%	1.10%	3.01%	7.31%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.33%	57.33%	56.52%	55.32%	55.07%	55.70%	55.18%	53.73%	52.57%	52.56%	55.12%
EBITDA Margin	11.10%	20.80%	26.88%	19.98%	17.44%	21.31%	16.32%	14.79%	10.88%	7.23%	15.76%
Operating Margin	4.97%	15.18%	20.75%	14.18%	11.21%	15.35%	9.95%	8.63%	4.30%	-0.44%	8.81%
EBIT Margin	4.97%	15.18%	20.75%	14.18%	11.21%	15.35%	9.95%	8.63%	4.30%	-0.44%	8.81%
Profit (Net Income) Margin	1.88%	9.76%	15.47%	9.03%	6.31%	10.11%	5.20%	4.32%	0.62%	10.60%	16.78%
Tax Burden Percent	78.68%	77.34%	86.77%	79.91%	77.54%	81.29%	78.09%	78.82%	74.43%	-252.24%	293.72%
Interest Burden Percent	48.08%	83.13%	85.92%	79.64%	72.60%	81.06%	66.93%	63.54%	19.25%	961.59%	64.80%
Effective Tax Rate	21.32%	22.66%	13.23%	20.09%	22.46%	18.71%	21.91%	21.18%	25.57%	0.00%	-193.72%
Return on Invested Capital (ROIC)	2.82%	8.46%	12.83%	8.01%	6.09%	8.74%	5.19%	4.56%	2.15%	-0.20%	17.51%
ROIC Less NNEP Spread (ROIC-NNEP)	2.10%	7.71%	11.98%	7.22%	5.34%	7.95%	4.40%	3.75%	1.27%	3.04%	14.54%
Return on Net Nonoperating Assets (RNNOA)	2.08%	7.85%	13.06%	8.47%	6.63%	9.94%	5.78%	5.02%	1.42%	3.35%	16.67%
Return on Equity (ROE)	4.90%	16.31%	25.89%	16.48%	12.72%	18.68%	10.97%	9.58%	3.57%	3.16%	34.18%
Cash Return on Invested Capital (CROIC)	6.88%	5.65%	5.88%	5.76%	5.15%	4.72%	4.40%	1.89%	-16.40%	-16.96%	-12.92%
Operating Return on Assets (OROA)	2.84%	8.61%	11.52%	7.86%	6.11%	8.31%	5.04%	4.47%	2.30%	-0.22%	4.66%
Return on Assets (ROA)	1.07%	5.54%	8.59%	5.00%	3.44%	5.48%	2.63%	2.24%	0.33%	5.45%	8.86%
Return on Common Equity (ROCE)	4.90%	16.31%	25.89%	16.48%	12.72%	18.68%	10.97%	9.58%	3.57%	3.16%	34.18%
Return on Equity Simple (ROE_SIMPLE)	12.15%	0.00%	14.12%	11.18%	9.64%	0.00%	7.28%	11.32%	-12.46%	0.00%	-11.55%
Net Operating Profit after Tax (NOPAT)	13	41	57	38	27	41	24	22	9.45	-0.77	71
NOPAT Margin	3.91%	11.74%	18.00%	11.33%	8.69%	12.47%	7.77%	6.80%	3.20%	-0.31%	25.89%
Net Nonoperating Expense Percent (NNEP)	0.72%	0.75%	0.85%	0.79%	0.75%	0.78%	0.79%	0.81%	0.88%	-3.24%	2.97%
Return On Investment Capital (ROIC_SIMPLE)	0.67%	2.17%	-	-	-	2.26%	-	-	-	-0.04%	-
Cost of Revenue to Revenue	44.67%	42.67%	43.48%	44.68%	44.93%	44.30%	44.82%	46.27%	47.43%	47.44%	44.88%
SG&A Expenses to Revenue	46.33%	38.35%	31.49%	36.89%	39.50%	36.07%	41.14%	40.83%	44.03%	48.13%	41.66%
R&D to Revenue	4.03%	3.81%	4.28%	4.25%	4.35%	4.29%	4.09%	4.27%	4.24%	4.87%	4.64%
Operating Expenses to Revenue	50.36%	42.16%	35.77%	41.14%	43.86%	40.36%	45.23%	45.10%	48.27%	53.00%	46.30%
Earnings before Interest and Taxes (EBIT)	16	52	66	47	35	50	30	27	13	-1.10	24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	36	72	85	66	54	70	50	47	32	18	43
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.91	2.20	2.38	2.42	2.87	3.99	3.86	5.28	4.17	3.56	3.36
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.42	1.62	1.72	1.67	1.95	2.68	2.63	3.62	2.85	2.54	2.25
Price to Earnings (P/E)	15.72	15.97	16.83	21.66	29.82	51.69	52.97	46.66	0.00	0.00	0.00
Dividend Yield	1.32%	1.17%	1.11%	1.15%	1.00%	0.74%	0.80%	0.59%	0.78%	0.92%	1.01%
Earnings Yield	6.36%	6.26%	5.94%	4.62%	3.35%	1.93%	1.89%	2.14%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.48	1.62	1.70	1.69	1.88	2.40	2.28	2.86	2.33	2.08	1.98
Enterprise Value to Revenue (EV/Rev)	2.07	2.29	2.42	2.41	2.71	3.44	3.47	4.51	3.80	3.52	3.19
Enterprise Value to EBITDA (EV/EBITDA)	10.51	10.78	11.32	12.79	15.45	21.57	27.57	36.49	30.59	113.32	18.49
Enterprise Value to EBIT (EV/EBIT)	15.02	14.95	15.75	18.89	23.88	35.50	58.47	81.12	69.21	0.00	31.47
Enterprise Value to NOPAT (EV/NOPAT)	18.38	18.41	19.14	23.74	30.10	44.52	29.86	23.01	98.87	75.04	44.96
Enterprise Value to Operating Cash Flow (EV/OCF)	15.18	17.94	17.33	17.56	21.56	34.16	70.67	138.26	142.99	110.29	43.31
Enterprise Value to Free Cash Flow (EV/FCFF)	21.70	29.23	29.37	29.54	36.82	51.08	52.71	159.63	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.91	0.94	1.01	1.10	1.16	1.17	1.27	1.33	1.42	1.41	1.45
Long-Term Debt to Equity	0.91	0.94	1.01	1.09	1.16	1.17	1.18	1.25	1.32	1.32	1.45
Financial Leverage	0.99	1.02	1.09	1.17	1.24	1.25	1.31	1.34	1.12	1.10	1.15
Leverage Ratio	2.51	2.56	2.68	2.77	2.88	2.91	3.05	3.02	2.66	2.65	2.75
Compound Leverage Factor	1.21	2.13	2.31	2.21	2.09	2.36	2.04	1.92	0.51	25.52	1.78
Debt to Total Capital	47.71%	48.48%	50.21%	52.27%	53.69%	53.86%	55.99%	57.16%	58.60%	58.59%	59.14%
Short-Term Debt to Total Capital	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	3.90%	3.82%	3.83%	3.87%	0.01%
Long-Term Debt to Total Capital	47.68%	48.44%	50.17%	52.24%	53.65%	53.82%	52.08%	53.34%	54.76%	54.72%	59.12%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	52.29%	51.52%	49.79%	47.73%	46.31%	46.14%	44.01%	42.84%	41.40%	41.41%	40.86%
Debt to EBITDA	3.44	3.26	3.41	4.02	4.49	4.91	6.89	7.40	7.80	32.48	5.62
Net Debt to EBITDA	3.31	3.17	3.27	3.90	4.33	4.78	6.68	7.20	7.61	31.59	5.44
Long-Term Debt to EBITDA	3.44	3.26	3.41	4.02	4.48	4.90	6.41	6.91	7.29	30.34	5.62
Debt to NOPAT	6.02	5.57	5.77	7.46	8.74	10.13	7.46	4.67	25.23	21.51	13.67
Net Debt to NOPAT	5.78	5.42	5.54	7.24	8.44	9.87	7.24	4.54	24.60	20.92	13.23
Long-Term Debt to NOPAT	6.02	5.56	5.77	7.46	8.73	10.12	6.94	4.35	23.58	20.09	13.66
Altman Z-Score	1.97	2.11	2.12	2.03	2.07	2.41	2.14	2.52	2.09	1.88	1.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.26	2.30	2.27	2.34	2.18	1.98	1.66	1.74	1.90	1.96	2.75
Quick Ratio	0.91	0.94	0.96	1.01	0.94	0.86	0.69	0.73	0.75	0.74	1.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-10	-20	0.27	12	6.46	28	-35	-169	-301	-323	-209
Operating Cash Flow to CapEx	1,099.07%	1,072.72%	1,497.60%	1,206.30%	1,431.01%	1,161.59%	855.15%	588.94%	-90.43%	-204.33%	385.83%
Free Cash Flow to Firm to Interest Expense	-1.22	-2.22	0.03	1.28	0.67	2.99	-3.51	-16.94	-29.35	-34.20	-24.45
Operating Cash Flow to Interest Expense	5.01	4.89	5.53	4.51	3.04	5.93	4.60	2.67	-0.38	-1.23	3.03
Operating Cash Flow Less CapEx to Interest Expense	4.56	4.44	5.16	4.14	2.82	5.42	4.07	2.22	-0.79	-1.83	2.25
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.57	0.56	0.55	0.55	0.54	0.51	0.52	0.54	0.51	0.53
Accounts Receivable Turnover	5.69	5.45	5.58	5.45	5.55	5.74	5.47	5.28	5.54	5.57	5.89
Inventory Turnover	1.71	1.73	1.71	1.76	1.73	1.75	1.72	1.72	1.72	1.68	1.77
Fixed Asset Turnover	11.25	11.05	10.83	10.91	10.81	10.53	9.98	9.98	9.81	9.31	9.59
Accounts Payable Turnover	5.85	6.03	6.13	6.34	6.38	7.04	6.95	6.94	7.05	7.21	7.84
Days Sales Outstanding (DSO)	64.15	67.02	65.37	67.00	65.77	63.58	66.76	69.11	65.85	65.50	61.95
Days Inventory Outstanding (DIO)	214.06	211.45	213.53	207.98	211.07	208.87	212.10	212.63	211.62	217.03	205.65
Days Payable Outstanding (DPO)	62.41	60.56	59.56	57.58	57.23	51.88	52.50	52.57	51.78	50.64	46.59
Cash Conversion Cycle (CCC)	215.80	217.92	219.34	217.41	219.61	220.56	226.36	229.18	225.70	231.89	221.02
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,834	1,844	1,835	1,819	1,812	1,784	1,778	1,793	1,791	1,771	1,720
Invested Capital Turnover	0.72	0.72	0.71	0.71	0.70	0.70	0.67	0.67	0.67	0.65	0.68
Increase / (Decrease) in Invested Capital	23	60	57	25	21	12	59	191	310	322	280
Enterprise Value (EV)	2,723	2,995	3,120	3,072	3,413	4,282	4,053	5,132	4,174	3,680	3,410
Market Capitalization	1,867	2,114	2,217	2,135	2,456	3,332	3,071	4,119	3,136	2,654	2,407
Book Value per Share	$31.63	$31.16	$30.26	$28.63	$27.77	$27.13	$25.90	$25.52	$24.67	$24.46	$23.51
Tangible Book Value per Share	($14.17)	($14.90)	($16.20)	($18.10)	($19.26)	($20.23)	($22.00)	($22.93)	($24.15)	($24.66)	($25.84)
Total Capital	1,870	1,868	1,874	1,848	1,845	1,808	1,809	1,821	1,817	1,800	1,753
Total Debt	892	906	941	966	991	974	1,013	1,041	1,065	1,055	1,037
Total Long-Term Debt	891	905	940	965	990	973	942	971	995	985	1,036
Net Debt	857	881	902	937	957	950	982	1,013	1,038	1,026	1,003
Capital Expenditures (CapEx)	3.78	4.04	3.42	3.59	2.04	4.86	5.39	4.53	4.25	5.68	6.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)	321	338	321	329	311	281	289	304	333	325	333
Debt-free Net Working Capital (DFNWC)	357	363	359	358	345	306	320	332	359	354	366
Net Working Capital (NWC)	356	362	359	357	344	305	249	262	289	285	366
Net Nonoperating Expense (NNE)	6.52	6.85	8.03	7.67	7.44	7.73	7.82	7.88	7.63	-27	25
Net Nonoperating Obligations (NNO)	857	881	902	937	957	950	982	1,013	1,038	1,026	1,003
Total Depreciation and Amortization (D&A)	20	19	19	19	19	20	19	20	19	19	19
Debt-free, Cash-free Net Working Capital to Revenue	24.40%	25.87%	24.92%	25.80%	24.66%	22.60%	24.77%	26.70%	30.27%	31.13%	31.12%
Debt-free Net Working Capital to Revenue	27.09%	27.74%	27.90%	28.07%	27.35%	24.55%	27.38%	29.15%	32.69%	33.90%	34.24%
Net Working Capital to Revenue	27.04%	27.69%	27.85%	28.01%	27.29%	24.50%	21.34%	23.03%	26.34%	27.23%	34.22%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.19	$1.09	$1.59	$0.97	$0.64	$1.07	$0.52	$0.45	$0.06	$0.95	$1.51
Adjusted Weighted Average Basic Shares Outstanding	30.97M	30.91M	30.86M	30.81M	30.78M	30.78M	30.74M	30.66M	30.51M	30.50M	30.47M
Adjusted Diluted Earnings per Share	$0.19	$1.09	$1.57	$0.96	$0.63	$1.05	$0.50	$0.43	$0.06	$1.02	$1.48
Adjusted Weighted Average Diluted Shares Outstanding	31.15M	30.91M	31.11M	31.11M	31.27M	30.78M	31.69M	31.80M	31.20M	30.50M	31.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.94M	30.91M	30.89M	30.83M	30.80M	30.78M	30.75M	30.74M	30.58M	30.50M	30.48M
Normalized Net Operating Profit after Tax (NOPAT)	13	41	57	38	27	41	24	22	9.45	-0.77	17
Normalized NOPAT Margin	3.91%	11.74%	18.00%	11.33%	8.69%	12.47%	7.77%	6.80%	3.20%	-0.31%	6.17%
Pre Tax Income Margin	2.39%	12.62%	17.83%	11.30%	8.14%	12.44%	6.66%	5.48%	0.83%	-4.20%	5.71%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.93	5.93	7.10	4.91	3.65	5.28	3.02	2.74	1.24	-0.12	2.84
NOPAT to Interest Expense	1.52	4.58	6.16	3.92	2.83	4.29	2.36	2.16	0.92	-0.08	8.34
EBIT Less CapEx to Interest Expense	1.47	5.47	6.73	4.54	3.44	4.77	2.49	2.29	0.82	-0.72	2.05
NOPAT Less CapEx to Interest Expense	1.06	4.13	5.79	3.55	2.62	3.78	1.82	1.71	0.51	-0.68	7.56
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	20.78%	18.62%	18.69%	24.96%	29.82%	38.01%	42.17%	27.63%	-25.80%	-29.73%	-28.65%
Augmented Payout Ratio	20.78%	18.62%	18.69%	24.96%	29.82%	38.01%	42.17%	27.63%	-25.80%	-116.02%	-112.71%

Frequently Asked Questions About CONMED's Financials

When does CONMED's financial year end?

According to the most recent income statement we have on file, CONMED's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has CONMED's net income changed over the last 10 years?

CONMED's net income appears to be on an upward trend, with a most recent value of $132.42 million in 2024, rising from $32.19 million in 2014. The previous period was $64.46 million in 2023. Find out what analysts predict for CONMED in the coming months.

What is CONMED's operating income?

CONMED's total operating income in 2024 was $200.33 million, based on the following breakdown:

Total Gross Profit: $733.03 million
Total Operating Expenses: $532.71 million

How has CONMED revenue changed over the last 10 years?

Over the last 10 years, CONMED's total revenue changed from $740.06 million in 2014 to $1.31 billion in 2024, a change of 76.6%.

How much debt does CONMED have?

CONMED's total liabilities were at $1.34 billion at the end of 2024, a 8.3% decrease from 2023, and a 159.9% increase since 2014.

How much cash does CONMED have?

In the past 10 years, CONMED's cash and equivalents has ranged from $17.51 million in 2018 to $72.50 million in 2015, and is currently $24.46 million as of their latest financial filing in 2024.

How has CONMED's book value per share changed over the last 10 years?

Over the last 10 years, CONMED's book value per share changed from 21.12 in 2014 to 31.16 in 2024, a change of 47.6%.

Related Companies

This page (NYSE:CNMD) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONMED (CNMD) Financials

Frequently Asked Questions About CONMED's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CONMED (CNMD) Financials

Annual Income Statements for CONMED

Quarterly Income Statements for CONMED

Annual Cash Flow Statements for CONMED

Quarterly Cash Flow Statements for CONMED

Annual Balance Sheets for CONMED

Quarterly Balance Sheets for CONMED

Annual Metrics And Ratios for CONMED

Quarterly Metrics And Ratios for CONMED

Frequently Asked Questions About CONMED's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools